Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Asset disposition
Class action filed
Cellectar Biosciences, Inc. (CLRB) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/27/2021 GN Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico
03/11/2021 GN Cellectar to Participate at Upcoming Institutional Investor Conferences
03/05/2021 GN Cellectar to Participate at Upcoming Institutional Investor Conferences
03/02/2021 GN Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update
02/10/2021 GN Cellectar to Present at BIO CEO & Investor Digital Conference
01/27/2021 GN Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia
12/28/2020 GN Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
12/23/2020 GN Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
12/22/2020 GN Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement
11/09/2020 GN Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
08/17/2020 GN Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA
07/21/2020 GN Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting
07/01/2020 GN Cellectar Appoints Dr. John Friend as Chief Medical Officer
06/11/2020 GN Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles
06/05/2020 GN Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering
06/03/2020 GN Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering
06/01/2020 GN Cellectar Granted SME Status by the European Medicines Agency
05/26/2020 GN Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia
05/07/2020 GN Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update
03/09/2020 GN Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update
01/09/2020 GN Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
01/07/2020 GN Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer
01/06/2020 GN Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)
12/19/2019 GN Cellectar Biosciences to Present at Biotech Showcase 2020
12/16/2019 GN Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
12/13/2019 GN Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium
12/09/2019 GN Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference
11/12/2019 GN Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
10/30/2019 GN Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
09/30/2019 GN Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress
09/19/2019 GN Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference
09/16/2019 GN Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
09/04/2019 GN Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop
08/15/2019 GN Cellectar Appoints Dov Elefant as Chief Financial Officer
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy